Beeline Medicines reports promising Phase 2 lupus data

Beeline Medicines, a Bain‑backed startup, announced encouraging mid‑stage results for its lupus candidate afimetoran, a drug originally sourced from Bristol Myers Squibb.

The Phase 2 trial data were described as promising, suggesting the compound may have therapeutic potential for patients with lupus.

The positive readout underscores the value of reviving previously shelved assets and could draw further interest from investors and partners in the biotech sector.